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amily physicians are uniquely suited to deliver comprehensive, unfragmented family planning services to patients of all ages. 1 With access to an increasingly robust evidence base on ways to prevent or achieve pregnancy and treat sexually transmitted infections (STIs), clinicians are challenged to offer and manage the safest and most effective options available for patients with various medical conditions, social circumstances, adherence patterns, and financial barriers to care.
Approximately one-half of the 6.6 million pregnancies each year in the United States are unintended, and the rates are highest among young, poor, and minority women. 2 In 2008, women 15 to 44 years of age with incomes at or below the federal poverty level were five times more likely than women at the highest income level to become pregnant unintentionally. 2 Women who use contraception consistently and correctly account for only 5% of unintended pregnancies. 3 To help clinicians provide optimal sexual and reproductive health services, the Centers for Disease Control and Prevention (CDC) has released comprehensive, evidence-based recommendations that have been methodically and scientifically established by technical and expert panels 4 (eTable A). Recommendations pertaining to contraceptive management are addressed in this review. At every health care visit, clinicians should discuss family planning needs with patients of reproductive age and provide requested services as appropriate. 4 
Provision of Contraception
The CDC recommends a systematic approach to contraceptive counseling and education to ensure safe, high-quality care. Figure 1 includes a summary of the five steps clinicians should take when providing contraception to patients.
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Volume 91, Number 9 ◆ May 1, 2015 maintaining rapport is critical for success. [4] [5] [6] [7] [8] Clinicians should ask open-ended questions; demonstrate expertise, trustworthiness, accessibility, and empathy; ensure privacy and confidentiality; explain how personal information will be used; and encourage patients to ask questions.
STEP 2: OBTAIN CLINICAL AND SOCIAL INFORMATION
Contraceptive recommendations should be personalized, focusing on the patient's safety and reproductive life plan. 4 The interview should elicit, at minimum, menstrual, gynecologic, and obstetric history; medication allergies; infectious or chronic health conditions; and tobacco use. These may alter the patient's medical eligibility for a particular method 9, 10 (eTable B). Knowing the patient's contraceptive experience and intentions regarding pregnancy is useful. A sexual health assessment-including practices, partners, STI status, condom use, and recent intercourse-may aid in selecting and safely initiating appropriate contraception. 4 
STEP 3: WORK INTERACTIVELY TO HELP THE PATIENT SELECT THE MOST EFFECTIVE AND APPROPRIATE METHOD
Clinicians should discuss all available contraceptive methods that the patient can use safely, regardless of which are available on site. 4, 11 The CDC encourages a tiered approach to counseling, whereby the most effective and medically appropriate options are presented before less effective options 4, [12] [13] [14] [15] (eFigure A). Other factors that may be important to the patient should be considered, such as her ability to use the method correctly and consistently, and possible adverse effects. 4 Information on noncontraceptive benefits of various methods, such as a potential reduction in dysmenorrhea, abnormal uterine bleeding, or acne, may help patients select and adhere to medication regimens. 4 For patients with or at risk of an STI, dual-method contraception, which combines condoms and another method, should be discussed. 4, 16 Steps in Providing Contraceptive Services Medication adherence concerns apply to patients with substance use, mental illness, difficulties with medication regimens, and sociobehavioral factors. 4 For example, if intimate partner violence is suspected, in addition to providing appropriate safety referrals (e.g., to law enforcement and violence support groups), clinicians may offer long-acting reversible contraception to decrease barriers to contraception adherence. 4 
STEP 4: CONDUCT PHYSICAL ASSESSMENT
Clinicians should determine the patient's pregnancy status before initiating a contraceptive method; conduct a blood pressure evaluation before prescribing hormonal contraception; and perform a bimanual examination and cervical inspection before inserting an intrauterine device (IUD) or fitting a cervical cap. 4, 17 A bimanual examination is needed before diaphragm fitting. 4, 17 In patients with cervicitis or pelvic inflammatory disease, IUD placement should be deferred until appropriate treatment has occurred. 4, 9, 17 Requiring other preventive services (e.g., cervical cytology; breast examination; evaluation for STI, diabetes mellitus, dyslipidemia, liver disease, thrombophilia) can introduce barriers to contraceptive care; therefore, such services should be offered as optional adjuncts and not as prerequisites. 4, 18, 19 Testing for STIs can be performed at the time of IUD placement in asymptomatic patients, and should be performed if routine screening has not occurred according to CDC guidelines.
Monitoring weight may be useful, although weight does not preclude eligibility for any contraceptive method. 4, 9, 17 A recent Cochrane review suggested that mean weight gain from progestin-only methods was less than 2 kg (4.4 lb) at 12-month follow-up.
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STEP 5: INITIATE METHOD AND ESTABLISH PLAN
If it is reasonably certain that a patient is not pregnant (Table 1 4,17, [21] [22] [23] [24] ) and that she meets appropriate medical eligibility criteria, any contraceptive may be started immediately. 4, 9, 10, 17 If pregnancy status is uncertain, clinicians may consider same-day start of a nonintrauterine method to provide immediate coverage, and then order follow-up pregnancy testing two to four weeks later. 9, 17, 21, 22 A negative pregnancy test result is insufficient for definitively ruling out pregnancy because results can be affected by test characteristics, the time since most recent intercourse, and recent pregnancy. It may help confirm that pregnancy is unlikely in patients who meet the criteria in Table 1 4,17,21-24 ; accordingly, pregnancy testing is not universally required before initiating contraception. 17, 23, 24 To reduce barriers to care when prescribing combined contraceptives, the prescription for hormonal contraceptives should cover one year's supply, and condoms should be made readily available. 4, 17 If requested contraceptive services are unavailable, a temporary method should be established until the patient can be referred for further assessment. 4 Recommendations for backup contraception during method initiation and switching are provided in Table 2 .
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Clinicians should reserve adequate time to counsel patients, particularly on common adverse effects (e.g., abnormal uterine bleeding, weight gain), to help reduce inconsistent use or early method discontinuation. 4, 17, 20, 25, 26 Educational resources are presented in eTable A. Concern about forgetfulness may be mitigated by reminder systems (e.g., smartphone applications) or use of long-acting reversible contraception. 4, 17, 26 Documentation should include the patient's understanding of use, benefits, and risks, plus an individualized follow-up plan. 4, 26 The teach-back method, in which the patient is asked to repeat important points, may be helpful. 
Follow-Up Considerations
Patients should be advised to return at any time to discuss questions or concerns about Table 1 
. How to Be Reasonably Certain That a Woman Is Not Pregnant
A clinician can be reasonably certain that a woman is not pregnant if:
(1) The patient has no signs or symptoms of pregnancy and (2) The patient meets at least one of the following:
Is seven days or less after start of her normal menses
Has not had intercourse since the start of her last normal menses Has been correctly and consistently using a reliable method of contraception Is seven days or less after a spontaneous or induced abortion contraceptive method use, but for most women, routine follow-up visits are not required. 17 When patients present for other routine visits, clinicians should assess for satisfaction and concerns, changes in health status or medication use that might affect eligibility for continued use, and changes in blood pressure (if using a combined hormonal method). 4, 17 Patients who use methods inconsistently or incorrectly, or who experience vomiting or severe diarrhea (i.e., affecting absorption), should be counseled on appropriate backup contraception (Table 3   17 ). Irregular bleeding with contraceptives is generally not harmful, and may decrease with continued method use. 17, 27 Other reasons for bleeding may be considered, including inconsistent use, medication interactions, infection, pregnancy, and pathologic uterine conditions. 17, 27 If patients request treatment for bleeding, five to seven days of nonsteroidal anti-inflammatory drugs may be offered to those using the copper-containing IUD (Paragard), etonogestrel implant (Nexplanon), or depot medroxyprogesterone acetate (DepoProvera). Alternatively, patients who use an implant or depot medroxyprogesterone acetate may benefit from low-dose combined oral contraceptives or estrogen for 10 to 20 days. 17 Bleeding with the levonorgestrel-containing IUD (Mirena) tends to resolve in three to six months without treatment. 17 Patients who use combined hormonal methods without hormone-free intervals (e.g., continuous use) may skip contraceptive pills for three to four consecutive days to temporarily induce bleeding and endometrial thinning, although not more often than monthly or before the first 21 days of use. 17 If irregular bleeding persists and is unacceptable to the patient, the clinician should assist with choosing another contraceptive method. 17, 27 Women who use intrauterine contraception and who are diagnosed with pelvic inflammatory disease should be treated according to the CDC's STI treatment guidelines; however, the clinician may leave the device in place for two to three days and then reassess the patient for disposition. 17, 28 If the device is removed, emergency contraception should be offered if residual sperm are potentially present.
Special Populations
Clinicians should ensure that all patients-including special populations, such as those who have disabilities or limited English proficiency, or who identify as lesbian, gay, bisexual, or transgender-receive high-quality care in a nonjudgmental, accommodating environment. Sexual behaviors and pregnancy risk should not be assumed. 4, 15, [29] [30] [31] When evaluating males, clinicians should remember to ascertain the patient's sexual health care needs, including contraceptive, preconception, and STI services. 4 Condoms should be made available without additional evaluation, and the principles of the five contraceptive care steps should be applied. 4 Adolescents should be given the opportunity to privately discuss their family planning needs and to subsequently receive care in the context of relevant law. 4, 15, [32] [33] [34] Without assurances of confidentiality, adolescents are significantly less likely to use family planning services; however, parent-patient communication about sexual and reproductive health may be encouraged to foster support, access to services, contraceptive use, and healthy development.
4,15,34-38 Some adolescents may 
Emergency Contraception
Emergency contraceptives have been reviewed in American Family Physician, including oral methods and the copper-containing IUD received within five days of unprotected intercourse to reduce unintended pregnancy risk. 45 Notably, the CDC highlights that ulipristal (Ella) may be more effective than levonorgestrel formulations after the first 72 hours and for women who are overweight or obese. 17, 46, 47 The CDC also supports advance provision of emergency contraceptive pills. Any contraceptive method may be started after completion of emergency contraceptive pills. The patient should use a barrier method or abstain from intercourse for seven days (14 days after ulipristal use), and should take a pregnancy test if she does not experience withdrawal bleeding within three weeks. 17 Patients who vomit within three hours after using emergency contraceptive pills should take another dose, at which point an antiemetic may be offered. 17 As of 2013, Plan B One-Step is available over the counter to patients of any age. 49 
17,48
Postpregnancy Contraceptive Options
Clinicians should emphasize postpregnancy contraception counseling. Almost one-half of abortions are repeat abortions, and nearly one in five births to teenagers is a repeat birth. 50, 51 The CDC specifies time frames for postpregnancy contraception (Table 4) . 9, 10, 17 Estrogencontaining methods should be deferred until at least three or up to six weeks postpartum, partly because of the risk of venous thromboembolism. 10, 52 Progestin-only methods can be safely started immediately postpartum. 
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Contraception in Women Approaching Menopause
In the United States, the median age of menopause is 51 years, but the normal range is from 40 to 60 years. 53, 54 Because there is no reliable test to verify permanent cessation of fertility, it is prudent to consider contraceptive use to prevent unintended pregnancy until menopause, or at least until 50 to 55 years of age. 17, 54 All contraceptive methods are considered U.S. Medical Eligibility Criteria category 1 or 2 (i.e., no restriction, or advantages generally outweigh theoretical or proven risks, respectively) based on the patient's age alone. However, clinicians must balance risks of pregnancy at advanced maternal age against risks of contraceptivesparticularly those containing estrogen, which may precipitate acute cardiovascular and thromboembolic events. 9, 17 Patients should be screened for preexisting conditions that affect medical eligibility criteria.
9,17
Sterilization Several permanent sterilization options are available in the United States, including abdominal, laparoscopic, or hysteroscopic tubal ligation for women and vasectomy for men 17, [55] [56] [57] (eTable C). Patients should be counseled about the intended irreversibility of these procedures and the availability of long-acting reversible contraception.
Data Sources: A PubMed search was completed using the MeSH function with the key phrase contraception combined with at least one of the following terms: effectiveness, safety, recommendations, guidelines, adolescent, female, or male. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were Essential Evidence Plus, the Cochrane Database of Systematic Reviews, and the U.S. Preventive Services Task Force website. The references of the relevant CDC resources were reviewed, as were the references from the systematic reviews generated to create the highlighted CDC resources. 
BEST PRACTICES IN GYNECOLOGY -RECOMMENDATIONS FROM THE CHOOSING WISELY CAMPAIGN
SORT: KEY RECOMMENDATIONS FOR PRACTICE
Clinical recommendations
Evidence rating References
Clinicians should consider a tiered approach to contraceptive counseling, whereby the most effective and appropriate options are presented before less effective options.
C 4, 12-15
Requiring prerequisite preventive services, such as cervical cytology; breast examination; or evaluation for sexually transmitted infections, diabetes mellitus, dyslipidemia, liver disease, or thrombophilia, can introduce unnecessary barriers to contraceptive care.
If a patient's pregnancy status is uncertain, clinicians may consider same-day start of a nonintrauterine method to provide immediate coverage, and should order follow-up pregnancy testing two to four weeks later.
Prescription of hormonal contraceptives should preferentially cover one year's supply to decrease barriers to care.
C 4
Family planning services should be offered to adolescents with assurances of confidentiality, in the context of relevant law. Common contraceptive options are evaluated based on common patient characteristics and medical conditions, and are assigned a numerical value based on evidence review: 1 = A condition for which there is no restriction on the use of the contraceptive method 2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks 3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method 
